Anti-CD276 CARs Target Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for solid tumors, have a poor prognosis and lack effective solutions, with many patients dying from cancer due to the limited availability of advanced therapies.
Innovation Solution
Development of polypeptides and proteins that specifically bind to CD276, a protein overexpressed in various cancers, to elicit an antigen-specific response, targeting and destroying cancer cells, and enhancing anti-cancer immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat cancer, then some cancer cells are killed, but the prognosis for solid tumors remains poor and many patients still die from cancer
Solution Approach 1:
The patent uses chimeric antigen receptors (CARs) as intermediary molecules that bridge the immune system and cancer cells. The CARs express anti-CD276 single-chain variable fragments (scFv) that specifically bind to CD276 on cancer cells, while the intracellular domain transmits activation signals to immune cells, thereby mediating targeted cancer cell destruction without the broad toxicity of chemotherapy
Solution Approach 2:
The patent extracts and isolates the specific antigen-binding function (anti-CD276 scFv) from the complete antibody structure, incorporating only the essential antigen-recognition domain into the CAR construct. This extraction allows for precise targeting of CD276-expressing cancer cells while minimizing off-target effects and improving treatment specificity
2Adaptability or versatility
If conventional cancer treatments are applied, then some tumors are treated, but effective solutions for solid tumors are lacking and treatment options are limited
Solution Approach 1:
The patent creates a universal CAR platform that can target CD276, a protein overexpressed in multiple types of solid tumors including ovarian, colorectal, lung, and prostate cancers. This multi-functional approach allows a single CAR construct to potentially treat various CD276-positive solid tumors, expanding treatment availability across different cancer types
Solution Approach 2:
The patent modifies the CAR construct parameters by incorporating specific anti-CD276 scFv sequences with optimized binding affinity and specificity. The CAR design includes modified signaling domains and regulatory elements that enhance T cell activation, persistence, and anti-tumor efficacy, thereby improving the reliability of treatment for solid tumors
Data Source
AI summary
Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.